AlphaCore Capital LLC boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 7.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,844 shares of the biopharmaceutical company’s stock after acquiring an additional 695 shares during the period. AlphaCore Capital LLC’s holdings in Gilead Sciences were worth $759,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in GILD. Sanctuary Wealth Management L.L.C. bought a new stake in shares of Gilead Sciences during the second quarter worth approximately $30,000. Steward Financial Group LLC bought a new stake in shares of Gilead Sciences during the 2nd quarter valued at $31,000. Venturi Wealth Management LLC bought a new position in shares of Gilead Sciences in the 1st quarter worth $36,000. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Gilead Sciences during the first quarter worth $36,000. Finally, Western Pacific Wealth Management LP increased its holdings in Gilead Sciences by 1,640.6% in the first quarter. Western Pacific Wealth Management LP now owns 557 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 525 shares during the last quarter. 82.33% of the stock is currently owned by institutional investors and hedge funds.
In related news, CFO Andrew D. Dickinson sold 5,000 shares of the business’s stock in a transaction on Tuesday, October 17th. The shares were sold at an average price of $80.00, for a total transaction of $400,000.00. Following the transaction, the chief financial officer now directly owns 104,003 shares in the company, valued at $8,320,240. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, insider Merdad Parsey sold 1,501 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $76.99, for a total value of $115,561.99. Following the completion of the sale, the insider now directly owns 70,130 shares of the company’s stock, valued at $5,399,308.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Andrew D. Dickinson sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, October 17th. The stock was sold at an average price of $80.00, for a total value of $400,000.00. Following the transaction, the chief financial officer now owns 104,003 shares of the company’s stock, valued at $8,320,240. The disclosure for this sale can be found here. 0.21% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
Gilead Sciences Stock Performance
Shares of GILD opened at $74.72 on Wednesday. The stock has a market capitalization of $93.10 billion, a price-to-earnings ratio of 16.03, a PEG ratio of 0.85 and a beta of 0.32. Gilead Sciences, Inc. has a 12 month low of $72.87 and a 12 month high of $89.74. The firm has a fifty day simple moving average of $76.81 and a 200 day simple moving average of $77.38. The company has a current ratio of 1.34, a quick ratio of 1.20 and a debt-to-equity ratio of 1.08.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported $2.29 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.38. The company had revenue of $7.05 billion during the quarter, compared to the consensus estimate of $6.81 billion. Gilead Sciences had a net margin of 21.45% and a return on equity of 39.30%. The company’s quarterly revenue was up .1% on a year-over-year basis. During the same period in the prior year, the business posted $1.90 EPS. Research analysts forecast that Gilead Sciences, Inc. will post 6.76 EPS for the current fiscal year.
Gilead Sciences Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be paid a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a dividend yield of 4.01%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s dividend payout ratio is currently 64.38%.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.
- Five stocks we like better than Gilead Sciences
- What is ChatGPT Stock? How to Invest in It
- Datadog is about to hit 52-week highs, and there’s more to come
- Following Congress Stock Trades
- Left for dead, Tower Semiconductor is a phoenix rising
- Airline Stocks – Top Airline Stocks to Buy Now
- 3 specialty apparel makers ready to spring higher
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.